Cystic Fibrosis Market Size, Share, Opportunities, And Trends By Drug Class (CFTR Modulators, Mucolytics, Brochodilators, Others), By Route Of Administration (Oral, Parenteral), By Distribution Channel (Hospital, Retail Pharmacies, Others), And By Geography - Forecasts From 2024 To 2029

  • Published : Jan 2024
  • Report Code : KSI061616143
  • Pages : 145

The cystic fibrosis market was valued at US$9,291.199 million in 2022.

The cells that make mucus, perspiration, and digestive fluids are impacted by cystic fibrosis. The secretions clog up tubes, ducts, and passages rather than lubricating them, particularly in the pancreas and lungs. Cystic fibrosis runs in families because cystic fibrosis requires two different gene variations to grow, the ailment is considered to be recessive.

Driving factors for the cystic fibrosis market

Increasing industry investment in R&D research along with other technical developments in the therapeutic field creates new growth opportunities for industry participants. A wearable sensor was created by NIH researchers to aid in the diagnosis and tracking of illness development. The sensor picks up the patients' bodies' abnormal salt balance and wirelessly transmits the information for examination. Throughout the forecast period, it is predicted that the cystic fibrosis market will grow due to increased innovation in the creation of novel treatments and pharmaceutical products to treat the condition.

Growing prevalence of cystic fibrosis

According to a recent estimate by the Cystic Fibrosis Foundation published in 2022, the number of people with cystic fibrosis has grown over the previous ten years. Nearly 40,000 children and adults suffer from cystic fibrosis in the United States, while an estimated 105,000 people worldwide have received a CF diagnosis fueling the cystic fibrosis market. The number of individuals with CF was last estimated to be over 30,000 in the United States and 70,000 worldwide in 2012. The Cystic Fibrosis Foundation Patient Registry and the Vital Statistics of the United States were used to get the most recent estimate of the overall number of CF patients.

Growing popularity for CFTR

As a chloride channel in the body, the transmembrane conductance regulator (CFTR) protein aids in controlling the movement of sodium and chlorine into and out of the cell membranes of the lungs and other organs. CFTR modulators improve cellular body function and patients' quality of life while reducing lung flare-ups and respiratory symptoms. The cystic fibrosis market's largest share is anticipated to belong to CFTR medications. Additionally, the development of the business will be fueled by additional cutting-edge treatments including triple combination medications with CFTR modulators.

Various product innovations by key players

The cystic fibrosis market is expanding due to the impending launch of medications for the treatment of CF. During the anticipated period, cystic fibrosis market expansion will be aided by the introduction of medications that target the faults in diseased people's cells and the likelihood that the medications will change the lives of many people. Additionally, it is believed that growth in the disease's prevalence is the main factor driving the cystic fibrosis market. This is speeding up the launch of recently discovered pipeline drugs required for the treatment of critically ill patients.

Increase in government initiatives

Through its efforts to provide access to therapies for those who have cystic fibrosis, the government is seeking to increase demand for products in the cystic fibrosis sector. For instance, in April 2023, Trikafta (elexacaftor, tezacaftor, ivacaftor, and ivacaftor) was made available via the Pharmaceutical Benefits Scheme (PBS) for cystic fibrosis patients between the ages of 6 and 11 years old. Cystic fibrosis patients and their families' lives are anticipated to be significantly affected by the advent of Trikafta for this particular age range. Families can get Trikafta through PBS for a maximum price of $30 per prescription or $7.30 with a concession card for children aged 6 to 11, fuelling the cystic fibrosis market growth throughout the anticipated timeframe.

Rising research & development in the market

Growing market revenue is mostly being driven by rising therapeutic R&D investments. For instance, in January 2023, Gensaic, a business that wants to reinvent gene therapy, announced that it has received money from the Cystic Fibrosis Foundation to research a gene therapy for the disease. The rising frequency of cystic fibrosis patients, higher demand for alternative therapies, and ongoing research & development of more sophisticated drugs are some of the main factors propelling revenue growth in the cystic fibrosis market.

Increasing clinical trials in the cystic fibrosis market

The cystic fibrosis market is expanding as a result of a range of treatments available. Nebulized antibiotic therapy lowers lung damage and enhances lung function in patients with chronic lung disease. A randomized controlled study of azithromycin FEV1 therapy shows a decrease in exacerbations and an improvement in quality of life. Further, in June 2023, a potentially ground-breaking new therapy for cystic fibrosis is currently undergoing clinical testing. This promising inhalable molecular prosthetic was developed by researchers at the Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign and the Carver College of Medicine at the University of Iowa in collaboration with the spin-out biotechnology company, Cystetic Medicines. It aims to improve lung function in CF patients who are not responding to existing treatments.

In North America, it is projected that the cystic fibrosis market will grow steadily. 

The North American region is anticipated to secure a sizable cystic fibrosis market share and is anticipated to expand significantly during the predicted period due to the rising prevalence of cystic fibrosis and the wide range of available treatments in the area. Regional cystic fibrosis market expansion will be fueled by increased financing for research and development studies on medications for cystic fibrosis and other beneficial government initiatives. The cystic fibrosis community can now discuss the most recent advancements in R&D due to educational forums offered by the North American Cystic Fibrosis Conference (NACFC). Other elements, including the existence of significant cystic fibrosis market competitors, a sophisticated healthcare infrastructure, and reimbursements, are anticipated to fuel cystic fibrosis market expansion.

Market Key Developments

  • In September 2022, the multi-year agreement between CytoReason and Pfizer has been extended, and Pfizer can use CytoReason's AI technology in its drug development initiatives.
  • In July 2022, The Cincinnati Children's Hospital Medical Centre announced a partnership with the Boomer Esiason Foundation (BEF) and the research intelligence firm Epistemic AI that will enable the division of pulmonary medicine to use artificial intelligence (AI) to speed up clinical research on cystic fibrosis and respiratory diseases.
  • In April 2022, The Bakar BioEnginuity Hub's incubator, Bakar Labs, and the Cystic Fibrosis Foundation jointly launched the first-ever "Golden Ticket" Competition to find the next promising cystic fibrosis drug.

Cystic Fibrosis Market Scope:


Report Metric Details
Market Size Value in 2022 US$9,291.199 million
Growth Rate CAGR during the forecast period
Base Year 2022
Forecast Period 2024 – 2029
Forecast Unit (Value) USD Million
Segments Covered
  • Drug Class
  • Route of Administration
  • Distribution Channel
  • Geography
Companies Covered
Regions Covered North America, South America, Europe, Middle East and Africa, Asia Pacific
Customization Scope Free report customization with purchase



  • By Drug Class
    • CFTR Modulators
    • Mucolytics
    • Brochodilators
    • Others
  • By Route of Administration
    • Oral
    • Parenteral
  • By Distribution Channel
    • Hospital
    • Retail Pharmacies
    • Others
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Indonesia
      • Thailand
      • Others


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Assumptions


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. CFTR Modulators

5.3. Mucolytics

5.4. Brochodilators

5.5. Others


6.1. Introduction

6.2. Oral

6.3. Parenteral


7.1. Introduction

7.2. Hospital

7.3. Retail Pharmacies

7.4. Others


8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others


9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations


10.1. Vertex Pharmaceuticals

10.2. Pfizer

10.3. Spirovant

10.4. Mayo Clinic

10.5. Evaluate Pharma

10.6. Krystal Biotech

10.7. Kalydeco

10.8. Sionna Therapeutics

10.9. Chiesi Cystic Fibrosis

10.10. Verona Pharma

Vertex Pharmaceuticals



Mayo Clinic

Evaluate Pharma

Krystal Biotech


Sionna Therapeutics

Chiesi Cystic Fibrosis

Verona Pharma